Application of extracellular gadolinium-based MRI contrast agents and the risk of nephrogenic systemic fibrosis

RoFo Fortschritte auf dem Gebiet der Rontgenstrahlen und der Bildgebenden Verfahren

Volumn 186, Issue 7, 2014, Pages 661-669

  Heverhagen, J T ^a   Krombach, G A ^b   Gizewski, E ^c  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY HOSPITAL GIESSEN   (Germany)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

contrast agents; gadolinium; MR imaging; safety

Indexed keywords

GADOBENATE DIMEGLUMINE; GADOBUTROL; GADODIAMIDE; GADOFOSVESET; GADOLINIUM; GADOLINIUM CHELATE; GADOLINIUM PENTETATE MEGLUMINE; GADOTERIC ACID; GADOVERSETAMIDE; GADOXETIC ACID;

ACUTE KIDNEY FAILURE; BREAST FEEDING; CONTRAST ENHANCEMENT; DISEASE COURSE; DRUG ELIMINATION; DRUG EXCRETION; ELECTROPHYSIOLOGY; EUROPEAN MEDICINES AGENCY; FOOD AND DRUG ADMINISTRATION; GLOMERULUS FILTRATION RATE; HIGH RISK POPULATION; HUMAN; LIVER; NEPHROGENIC SYSTEMIC FIBROSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PREGNANT WOMAN; PRIORITY JOURNAL; REVIEW; SPINDLE CELL;

CONTRAST MEDIA; EVIDENCE-BASED MEDICINE; GADOLINIUM; HUMANS; MAGNETIC RESONANCE IMAGING; NEPHROGENIC FIBROSING DERMOPATHY; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS;

EID: 84902776199     PISSN: 14389029     EISSN: 14389010     Source Type: Journal    
DOI: 10.1055/s-0033-1356403     Document Type: Review

References (57)

1. Cowper S. E., Robin H. S., Steinberg S. M. et al. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. The Lancet: 2000; 356 1000 1001
2. Perez-Rodriguez J., Lai S., Ehst B. D. et al. Nephrogenic systemic fibrosis: incidence, associations, and effect of risk factor assessment - report of 33 cases. Radiology: 2009; 250 371 377
3. Kribben A., Witzke O., Hillen U. et al. Nephrogenic systemic fibrosis: pathogenesis, diagnosis, and therapy. J Am Coll Cardiol: 2009; 53 1621 1628
4. Jalandhara N., Arora R., Batuman V. Nephrogenic Systemic Fibrosis and Gadolinium-Containing Radiological Contrast Agents: An Update. Clin Pharmacol Ther: 2011; 89 920 923
5. Grobner T. Gadolinium - a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant: 2006; 21 1104 1108
6. Marckmann P., Skov L., Rossen K. et al. Nephrogenic Systemic Fibrosis: Suspected Causative Role of Gadodiamide Used for Contrast-Enhanced Magnetic Resonance Imaging. J Am Soc Nephrol: 2006; 17 2359 2362 (Pubitemid 44300951)
7. Bennett C. L., Qureshi Z. P., Sartor A. O. et al. Gadolinium-induced nephrogenic systemic fibrosis: the rise and fall of an iatrogenic disease. Clinical Kidney Journal: 2012; 5 82 88
8. Gupta A., Shamseddin M. K., Khaira A. Pathomechanisms of nephrogenic systemic fibrosis: new insights. Clin Exp Dermatol: 2011; 36 763 768
9. Collidge T. A., Thomson P. C., Mark P. B. et al. Gadolinium-enhanced MR Imaging and Nephrogenic Systemic Fibrosis: Retrospective Study of a Renal Replacement Therapy Cohort. Radiology: 2007; 245 168 175 (Pubitemid 47417800)
10. Wahba I. M., Simpson E. L., White K. Gadolinium Is Not the Only Trigger for Nephrogenic Systemic Fibrosis: Insights From Two Cases and Review of the Recent Literature. Am J Transplant: 2007; 7 2425 2432 (Pubitemid 47347864)
11. Cowper S. E., Boyer P. J. Nephrogenic systemic fibrosis: an update. Curr Rheumatol Rep: 2006; 8 151 157 (Pubitemid 44623984)
12. Cowper S. E., Rabach M., Girardi M. Clinical and histological findings in nephrogenic systemic fibrosis. European Journal of Radiology: 2008; 66 191 199
13. Becker S., Walter S., Witzke O. et al. The German registry for nephrogenic systemic fibrosis: findings from 23 patients. Clin Nephrol: 2010; 73 426 430
14. FDA Public Health Advisory Gadolinium-containing Contrast Agents for Magnetic Resonance Imaging (MRI). 2006; www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm053112. htm (Stand 20.08.2013)
15. FDA New warnings required on use of gadolinium-based contrast agents. 2007; www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2010/ucm225286.htm (Stand 20.08.2013)
16. GE Healthcare Wichtige Information zur Arzneimittelsicherheit Omniscan und nephrogener systemischer Fibrose. 2/2007 www.bfarm.de/SharedDocs/1- Downloads/DE/Pharmakovigilanz/roteHandBriefe/2007/rhb-omniscan.pdf?-blob= publicationFile (Stand 20.08.2013)
17. Bayer Health Care Aktualisierte Sicherheitsinformation zu Magnevist und nephrogener systemischer Fibrose (NSF). 6/2007 www.akdae.de/ Arzneimittelsicherheit/RHB/Archiv/2007/46-20070625.pdf (Stand 20.08.2013)
18. High W. A., Ayers R. A., Chandler J. et al. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol: 2007; 56 21 26 (Pubitemid 46017000)
19. Salomonsson M., Braunstein T. H., Holstein-Rathlou N. H. et al. Na+-independent, nifedipine-resistant rat afferent arteriolar Ca2+ responses to noradrenaline: possible role of TRPC channels. Acta Physiol (Oxf): 2010; 200 265 278
20. Caille J. M., Lemanceau B., Bonnemain B. Gadolinium as a contrast agent for NMR. Am J Neuroradiol: 1983; 4 1041 1042 (Pubitemid 14229570)
21. Penfield J. G., Reilly R. F. Jr. What nephrologists need to know about gadolinium. Nat Clin Pract Nephrol: 2007; 3 654 668 (Pubitemid 350146964)
22. Frenzel T., Lengsfeld P., Schirmer H. et al. Stability of gadolinium-based magnetic resonance imaging contrast agents in human serum at 37 degrees C. Invest Radiol: 2008; 43 817 828
23. Schmitt-Willich H. Stability of linear and macrocyclic gadolinium based contrast agents. Br J Radiol: 2007; 80 581 582
24. Pietsch H., Pering C., Lengsfeld P. et al. Evaluating the role of zinc in the occurrence of fibrosis of the skin: A preclinical study. J Magn Reson Imaging: 2009; 30 374 383
25. Marckmann P., Skov L., Rossen K. et al. Case-control study of gadodiamide-related nephrogenic systemic fibrosis. Nephrol Dial Transplant: 2007; 22 3174 3178 (Pubitemid 350202540)
26. Rydahl C., Thomsen H. S., Marckmann P. High prevalence of nephrogenic systemic fibrosis in chronic renal failure patients exposed to gadodiamide, a gadolinium-containing magnetic resonance contrast agent. Invest Radiol: 2008; 43 141 144
27. Prince M. R., Zhang H., Morris M. et al. Incidence of nephrogenic systemic fibrosis at two large medical centers. Radiology: 2008; 248 807 816
28. Sato T., Ito K., Tamada T. et al. Tissue gadolinium deposition in renally impaired rats exposed to different gadolinium-based MRI contrast agents: Evaluation with inductively coupled plasma mass spectrometry (ICP-MS). Magn Reson Imaging: 2013; Epub ahead of print
29. Kirchin M. A., Pirovano G. P., Spinazzi A. Gadobenate dimeglumine (Gd-BOPTA). An overview. Invest Radiol: 1998; 33 798 809
30. Sieber M. A., Lengsfeld P., Walter J. et al. Gadolinium-based contrast agents and their potential role in the pathogenesis of nephrogenic systemic fibrosis: the role of excess ligand. J Magn Reson Imaging: 2008; 27 955 962 (Pubitemid 351614604)
31. Sieber M. A., Steger-Hartmann T., Lengsfeld P. et al. Gadolinium-based contrast agents and NSF: Evidence from animal experience. J Magn Reson Imaging: 2009; 30 1268 1276
32. Sieber M. A., Pietsch H., Walter J. et al. A preclinical study to investigate the development of nephrogenic systemic fibrosis: a possible role for gadolinium-based contrast media. Invest Radiol: 2008; 43 65 75
33. Sieber M. A., Lengsfeld P., Frenzel T. et al. Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions. Eur Radiol: 2008; 18 2164 2173
34. Lorusso V., Arbughi T., Tirone P. et al. Pharmacokinetics and tissue distribution in animals of gadobenate ion, the magnetic resonance imaging contrast enhancing component of gadobenate dimeglumine 0.5 M solution for injection (MultiHance). J Comput Assist Tomogr: 1999; 23 01 S181 S194 (Pubitemid 30027607)
35. Schuhmann-Giampieri G. Liver contrast media for magnetic resonance imaging. Interrelations between pharmacokinetics and imaging 167. Invest Radiol: 1993; 28 753 761 (Pubitemid 24081774)
36. Han G., Nguyen L. N., Macherla C. et al. Nitric Oxide-Releasing Nanoparticles Accelerate Wound Healing by Promoting Fibroblast Migration and Collagen Deposition. Am J Pathol: 2012; 180 1465 1473
37. Haemel A. K., Sadowski E. A., Shafer M. M. et al. Update on nephrogenic systemic fibrosis: are we making progress? Int J Dermatol: 2011; 50 659 666
38. Yang L., Krefting I., Gorovets A. et al. Nephrogenic Systemic Fibrosis and Class Labeling of Gadolinium-based Contrast Agents by the Food and Drug Administration. Radiology: 2012; 265 248 253
39. Giersig C. (BfArM). Sicherheit von gadoliniumhaltigen Kontrastmitteln unter dem Aspekt der Nephrogenen Systemischen Fibrose, Vortrag im Rahmen des Symposiums Kontrast verstärkte MR-Untersuchungen - praxisnah für den Alltag in Stuttgart 10/2010.
40. EMEA Assessment report for gadolinium-containing contrast agents. 2010; www.ema.europa.eu/docs/en-GB/document-library/Referrals-document/gadolinium-31 / WC500099538.pdf (Stand 20.08.2013)
41. Schneider G., Maas R., Schultze K. L. et al. Low-dose gadobenate dimeglumine versus standard dose gadopentetate dimeglumine for contrast-enhanced magnetic resonance imaging of the liver: an intra-individual crossover comparison. Invest Radiol: 2003; 38 85 94 (Pubitemid 36125892)
42. Achenbach M., Figiel J. H., Burbelko M. et al. Prospective comparison of image quality and diagnostic accuracy of 0.5 molar gadobenate dimeglumine and 1.0 molar gadobutrol in contrast-enhanced run-off magnetic resonance angiography of the lower extremities. J Magn Reson Imaging: 2010; 32 1166 1171
43. Bauner K. U., Reiser M. F., Huber A. M. Low dose gadobenate dimeglumine for imaging of chronic myocardial infarction in comparison with standard dose gadopentetate dimeglumine. Invest Radiol: 2009; 44 95 104
44. Thomsen H. S., Morcos S. K., Almen T. et al. Nephrogenic systemic fibrosis and gadolinium-based contrast media: updated ESUR Contrast Medium Safety Committee guidelines. Eur Radiol: 2013; 23 307 318
45. American College of Radiology Manual on Cotrast Media, Version 9. 2013; www.acr.org/~/media/ACR/Documents/PDF/QualitySafety/Resources/Contrast%20Manual/ 2013-Contrast-Media.pdf (Stand 20.08.2013)
46. ESUR Guidelines Version 8.1. 2013; http://www.esur.org/guidelines/en/ index.php (Stand 20.08.2013)
47. ESUR Summary NSF. 2013; http://www.esur.org/esur-guidelines/nsf (Stand 20.08.2013)
48. Yoshikawa K., Davies A. Safety of ProHance in special populations. Eur Radiol: 1997; 7 05 246 250
49. Kalb R. E., Helm T. N., Sperry H. et al. Gadolinium-induced nephrogenic systemic fibrosis in a patient with an acute and transient kidney injury. Br J Dermatol: 2008; 158 607 610 (Pubitemid 351239168)
50. Perez-Rodriguez J., Lai S., Ehst B. D. et al. Nephrogenic systemic fibrosis: incidence, associations, and effect of risk factor assessment - report of 33 cases. Radiology: 2009; 250 371 377
51. Bindschedler M. Swissmedic; Sicherheitsrelevante Information zu gadoliniumhaltigen Kontrastmitteln. Schweizerische Ärztezeitung 2006; 87: 29/30 1323 www.saez.ch/docs/saez/archiv/de/2006/2006-30/2006-30-686.PDF (Stand 20.08.2013)
52. Elmholdt T. R., Pedersen M., Jorgensen B. et al. Nephrogenic systemic fibrosis is only found among gadolinium-exposed kidney-insufficient patients: a case-control study from Denmark. Br J Dermatol: 2011; 165 828 836
53. Guerbet Updated safety information. 2011; www.guerbet.co.kr/fileadmin/ user-upload/websites/site-co/2011-28-February-Updated-information-about-NSF.pdf (Stand 20.08.2013)
54. Bayer Reports of NSF/NSF-like symptoms in possible association with the administration of Gadolinium-based contrast agents of Bayer. www.diagnostic-imaging.bayerscheringpharma.de/html/pdf/hcp/nsf/NSF-website-NSF- reports-Jan11.pdf (Stand 19.09.2011)
55. Neumann H. Optimark (gadoversetamide) U. S. Food and Drug Administration, Joint Meeting of the Cardiovascular and Renal Drugs and Drug Safety and Risk Management. 2009; www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/ UCM196229.pdf (Stand 20.08.2013)
56. Bracco Info-Brief NSF. Auf Anfrage bei Services.professional@bracco.com, (Stand 20.08.2013)
57. Bayer Health Care Briefing Document for Gadobutrol Injection. 2011; www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ PeripheralandCentralNervousSystemDrugsAdvisoryCommittee/UCM240357.pdf (Stand 20.08.2013)